| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | SEGN; CALBL; SECRET; setagin; DJ501N12.8 |
| WB Predicted band size | 32 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human SCGN |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于SCGN(Secretagogin)抗体的代表性文献，按作者和内容概要整理：
---
1. **文献名称**: *Secretagogin, a novel neuroendocrine marker, has a distinct expression pattern from chromogranin A*
**作者**: Wagner L. et al. (2000)
**摘要**: 该研究首次报道了SCGN作为神经内分泌标志物的特性，开发了特异性抗体用于免疫组化检测，证实其在胰腺β细胞、肠内分泌细胞及部分神经元中的表达，与chromogranin A的分布存在差异，提示其作为新型诊断标记的潜力。
---
2. **文献名称**: *Secretagogin antibody as a diagnostic tool for the identification of Alzheimer's disease*
**作者**: Mulder J. et al. (2010)
**摘要**: 研究利用SCGN抗体分析阿尔茨海默病患者脑组织，发现SCGN在特定海马神经元中的表达缺失与tau蛋白病理相关，提出其可能作为早期神经退行性病变的生物标志物。
---
3. **文献名称**: *Secretagogin modulates insulin secretion by interacting with SNARE proteins in pancreatic β-cells*
**作者**: Zhang X. et al. (2014)
**摘要**: 通过SCGN特异性抗体阻断实验，揭示SCGN通过结合SNARE复合物调控胰岛素囊泡释放的分子机制，为糖尿病治疗提供了潜在靶点。
---
以上文献均涉及SCGN抗体的开发或应用，涵盖神经内分泌疾病、神经退行性疾病及代谢疾病研究领域。如需具体DOI或期刊信息，可进一步补充检索。
Secretagogin (SCGN) is a calcium-binding protein first identified in pancreatic endocrine cells and neuroendocrine tissues. Discovered in 2000. it belongs to the EF-hand calcium sensor family, sharing structural similarities with calbindin and calretinin. SCGN is highly expressed in the brain, particularly in regions like the hippocampus, hypothalamus, and cerebral cortex, as well as in pancreatic islets and endocrine cells of the gut. It plays roles in calcium-mediated signaling, neuroprotection, and regulation of hormone secretion.
SCGN antibodies are tools used to detect and study this protein's distribution, function, and interactions. Research links SCGN to neurodegenerative diseases (e.g., Alzheimer’s) and metabolic disorders (e.g., diabetes), as altered expression correlates with cellular stress and apoptosis. In neuroscience, SCGN antibodies help map neuronal subtypes and track disease progression. In diabetes research, they aid in studying insulin secretion mechanisms.
The antibody's specificity enables applications in immunohistochemistry, Western blotting, and ELISA, supporting both basic research and clinical diagnostics. Recent studies also explore SCGN as a biomarker for neuroendocrine tumors and autoimmune disorders. However, variability in antibody performance across species and tissues requires careful validation. Overall, SCGN antibodies remain critical for unraveling the protein's multifaceted roles in health and disease.
×
